CD274 and urinary bladder carcinoma: Atezolizumab was the first PD-L1 inhibitor confirmed active in bladder cancer and is currently the only PD-L1 inhibitor approved by the FDA for patients with metastatic or locally advanced urothelial carcinoma based on promising overall response rates in clinical trials (Bellmunt et al., 2017).